
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics is a life sciences instrumentation company that provides an end-to-end solution for genome analysis with its scalable OGM platform, high-throughput Stratys system, and VIA platform for data integration. The company's strong sales growth potential and impressive technological advancements, such as the OMKar computational tool for constructing digital karyotypes and isotachophoresis for high-purity DNA and RNA isolation, make it a promising stock despite risks of lower market uptake or utilization and the need for additional capital in the next 12 months.
Bears say
Bionano Genomics is facing financial struggles with a negative cash flow from operations and a high level of debt, which may lead to the need for additional capital in the near future. Although the company reported a top- and bottom-line beat for 4Q25, they still experienced a YoY decline in revenue and have provided a lower revenue guidance for FY2026. Additionally, while OGM technology has potential for growth, the current published clinical evidence is limited and the company is heavily dependent on the success and adoption of this technology, which carries inherent risks.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares